目的 探討RET原癌基因與分化性甲狀腺癌關(guān)系的研究進展。
方法 采用文獻回顧的方法,對RET基因及編碼產(chǎn)物的結(jié)構(gòu),參與的細胞內(nèi)信號轉(zhuǎn)導,以及RET基因與分化性甲狀腺癌的關(guān)系的研究進展加以綜述。
結(jié)果 RET基因編碼酪氨酸激酶受體,參與細胞內(nèi)信號轉(zhuǎn)導,RET原癌基因重排是乳頭狀甲狀腺癌中常見的遺傳學事件。
結(jié)論 RET基因與分化性甲狀腺癌的發(fā)生、發(fā)展密切相關(guān),是該類腫瘤治療的一個新靶點。
引用本文: 唐波,姜軍. RET原癌基因與分化性甲狀腺癌關(guān)系的研究進展. 中國普外基礎(chǔ)與臨床雜志, 2004, 11(1): 89-91. doi: 復制
1. | Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement [J]. Cell, 1985; 42(2)∶581. |
2. | Pasini B, Hofstra RM, Yin L,et al.The physical map of the human RET protooncogene [J]. Oncogene, 1995; 11(9)∶1737. |
3. | Durbec P, MarcosGutierrez CV, Kilkenny, et al.GDNF signalling through the Ret receptor tyrosine kinase [J]. Nature, 1996; 381(6585)∶789. |
4. | Besset V, Scott RP, Ibanez CF.Signaling complexes and proteinprotein interactions involved in the activation of the Ras and phosphatidylinositol 3kinase pathways by the cRet receptor tyrosine kinase [J]. J Biol Chem, 2000; 275(50)∶39159. |
5. | De Vita G, Melillo RM, Carlomagno F, et al. Tyrosine 1062 RETMEN2A mediates activation of Akt (protein kinase B) and mitogenactivated protein kinase pathways leading to PC12 cell survival [J]. Cancer Res, 2000; 60(14)∶3727. |
6. | Hayashi H, Ichihara M, Iwashita T, et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell linederived neurotrophic factor [J]. Oncogene, 2000; 19(39)∶4469. |
7. | Alberti L, Borrello MG, Ghizzoni S, et al.Grb2 binding to the different isoforms of Ret tyrosine kinase [J]. Oncogene, 1998; 17(9)∶1079. |
8. | Arighi E, Alberti L, Torriti F, et al. Identification of Shc docking site on Ret tyrosine kinase [J]. Oncogene, 1997; 14(7)∶773. |
9. | Mercalli E, Ghizzoni S, Arighi E, et al.Key role of shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein [J]. Oncogene, 2001; 20(27)∶3475. |
10. | Musholt TJ, Musholt PB, Khaladj N, et al.Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma [J]. Surgery, 2000; 128(6)∶984. |
11. | Roque L, Nunes VM, Ribeiro C, et al.Karyotypic charaterization of papillary thyroid carcinoma [J]. Cancer, 2001; 92(10)∶2529. |
12. | Rabes HM.Gene rearrangements in radiationinduced thyroid carcinogenesis [J]. Med Pediatr Oncol, 2001; 36(5)∶574. |
13. | Sheils OM, O’leary JJ, Sweeney EC, et al.Assessment of ret/PTC1 rearrange ments in neoplastic thyroid tissue using TaqMan RTPCR [J]. J Pathol, 2000; 192(1)∶32. |
14. | Mai KT, Vaccani JP, Thomas J, et al. Immunostaining for ret oncogene proteins in papillary thyroid carcinoma: a correlation of ret immunoreactivity and potential of lymph node metastasis [J]. Thyroid, 2001; 11(9)∶859. |
15. | Basolo F, Molinaro E, Agate L, et al.RET protein expression has no prognostic impact on the longterm outcome of papillary thyroid carcinoma [J]. Eur J Endocrinol, 2001; 145(5)∶599. |
16. | Salvatore G, Nagata S, Billaud M, et al. Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase [J]. Biochem Biophys Res Commun, 2002; 294(4)∶813. |
17. | Hennige AM, Lammers R, Hoppner W, et al.Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1 [J]. Endocrinology, 2001; 142(10)∶4441. |
18. | Carlomagno F, Vitagliano D, Guida T, et al.The kinase inhibitor PP1 blocks tumor igenesis induced by RET oncogenes [J].Cancer Res, 2002; 62(4)∶1077. |
- 1. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement [J]. Cell, 1985; 42(2)∶581.
- 2. Pasini B, Hofstra RM, Yin L,et al.The physical map of the human RET protooncogene [J]. Oncogene, 1995; 11(9)∶1737.
- 3. Durbec P, MarcosGutierrez CV, Kilkenny, et al.GDNF signalling through the Ret receptor tyrosine kinase [J]. Nature, 1996; 381(6585)∶789.
- 4. Besset V, Scott RP, Ibanez CF.Signaling complexes and proteinprotein interactions involved in the activation of the Ras and phosphatidylinositol 3kinase pathways by the cRet receptor tyrosine kinase [J]. J Biol Chem, 2000; 275(50)∶39159.
- 5. De Vita G, Melillo RM, Carlomagno F, et al. Tyrosine 1062 RETMEN2A mediates activation of Akt (protein kinase B) and mitogenactivated protein kinase pathways leading to PC12 cell survival [J]. Cancer Res, 2000; 60(14)∶3727.
- 6. Hayashi H, Ichihara M, Iwashita T, et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell linederived neurotrophic factor [J]. Oncogene, 2000; 19(39)∶4469.
- 7. Alberti L, Borrello MG, Ghizzoni S, et al.Grb2 binding to the different isoforms of Ret tyrosine kinase [J]. Oncogene, 1998; 17(9)∶1079.
- 8. Arighi E, Alberti L, Torriti F, et al. Identification of Shc docking site on Ret tyrosine kinase [J]. Oncogene, 1997; 14(7)∶773.
- 9. Mercalli E, Ghizzoni S, Arighi E, et al.Key role of shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein [J]. Oncogene, 2001; 20(27)∶3475.
- 10. Musholt TJ, Musholt PB, Khaladj N, et al.Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma [J]. Surgery, 2000; 128(6)∶984.
- 11. Roque L, Nunes VM, Ribeiro C, et al.Karyotypic charaterization of papillary thyroid carcinoma [J]. Cancer, 2001; 92(10)∶2529.
- 12. Rabes HM.Gene rearrangements in radiationinduced thyroid carcinogenesis [J]. Med Pediatr Oncol, 2001; 36(5)∶574.
- 13. Sheils OM, O’leary JJ, Sweeney EC, et al.Assessment of ret/PTC1 rearrange ments in neoplastic thyroid tissue using TaqMan RTPCR [J]. J Pathol, 2000; 192(1)∶32.
- 14. Mai KT, Vaccani JP, Thomas J, et al. Immunostaining for ret oncogene proteins in papillary thyroid carcinoma: a correlation of ret immunoreactivity and potential of lymph node metastasis [J]. Thyroid, 2001; 11(9)∶859.
- 15. Basolo F, Molinaro E, Agate L, et al.RET protein expression has no prognostic impact on the longterm outcome of papillary thyroid carcinoma [J]. Eur J Endocrinol, 2001; 145(5)∶599.
- 16. Salvatore G, Nagata S, Billaud M, et al. Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase [J]. Biochem Biophys Res Commun, 2002; 294(4)∶813.
- 17. Hennige AM, Lammers R, Hoppner W, et al.Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1 [J]. Endocrinology, 2001; 142(10)∶4441.
- 18. Carlomagno F, Vitagliano D, Guida T, et al.The kinase inhibitor PP1 blocks tumor igenesis induced by RET oncogenes [J].Cancer Res, 2002; 62(4)∶1077.